Noninferiority trials

Handbook of Statistics in Clinical Oncology: Second Edition

Volumn , Issue , 2005, Pages 191-205

  Kopecky, Kenneth J ^a   Green, Stephanie ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859395299     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (20)

1. Wiens, B.L. Choosing an equivalence limit for noninferiority or equivalence trials. Contr. Clin. Trials, 23, 1, 2002.
2. Wang, H., Chow, S., and Li, G. On sample size calculation based on odds ratio in clinical trials. J. Biopharm. Stat., 12, 471, 2002.
3. Alberts, D.S. et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J. Clin. Oncol., 10, 706, 1992.
4. Rosen, L.S. et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J., 7, 377, 2001.
5. Major, P. et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol., 19, 558, 2001.
6. Michallet, M. et al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia, 18, 309, 2004.
7. Koch, A., and Röhmel, J. Hypothesis testing in the "gold standard" design for proving the efficacy of an experimental treatment relative to placebo and a reference. J. Biopharm. Stat. 14, 315, 2004.
8. D'Agostino, R.B., Massaro, J.M., and Sullivan, L.M. Non-inferiority trials: concepts and issues - the encounters of academic consultants in statistics. Stat. Med., 22, 169, 2003.
9. Jones, B. et al. Trials to assess equivalence: the importance of rigorous methods. BMJ 313, 36, 1996.
10. Wang, S.J., Hung, H.M.J., and Tsong, Y. Utility and pitfalls of some statistical methods in active controlled clinical trials. Contr. Clin. Trials, 23, 15, 2002.
11. Hung, H.M.J. et al. Some fundamental issues with noninferiority testing in active controlled trials. Stat. Med., 22, 213, 2003.
12. Rothman, M. et al. Design and analysis of non-inferiority mortality trials in oncology. Stat. Med., 22, 239, 2003.
13. Bennett, J.M. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int. J. Hemat., 72, 131, 2000.
14. Simon, R. Therapeutic equivalence trials, in Handbook of Statistics in Clinical Oncology, Crowley J., ed., Marcel Dekker, Inc., New York, 2001, chap. 10.
15. Fisher, L. Active control trials: what about a placebo? A method illustrated with clopridogrel, aspirin, and placebo. J. Amer. Coll. Cardiol., 31, 49A, 1998.
16. Hasselblad, V. and Kong, D.F. Statistical methods for comparison of placebo in active-control trials. Drug Inf. J., 35, 435, 2001.
17. Simon, R. Bayesian design and analysis of active control clinical trials. Biometrics, 55, 484, 1999.
18. Ibrahim, A. et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin. Cancer Res., 9, 2394, 2003.
19. CDER/CBER. Guidance for Industry. E9 Statistical Principles for Clinical Trials, Food and Drug Administration, 1998.
20. Krysan, D.J. and Kemper A.R. Claims of equivalence in randomized controlled trials of the treatment of bacterial meningitis in children. Pediatr. Infect. Dis. J., 21, 753, 2002.